Navigation Links
Medicare costs estimated to top $21.1 billion for 5 years of care for elderly cancer patients
Date:4/29/2008

The cost of cancer care for elderly Medicare patients varies by tumor type, stage at diagnosis, phase of care, and survival, according to a new study published online April 29 in the Journal of the National Cancer Institute. The 5-year cost is highest for patients with lung, colorectal, and prostate cancers. The estimated cost for 5 years of care for elderly Medicare patients diagnosed with cancer in 2004 is $21.1 billion.

Cost estimates for cancer care are useful for the development and implementation of national cancer programs and policies. As the United States population expands and ages, the incidence of cancer and its associated costs are expected to rise.

To estimate the cost of cancer care in the U.S., Robin Yabroff, Ph.D., of the National Cancer Institute in Bethesda, Md., and colleagues used the Surveillance, Epidemiology, and End Results (SEER) and SEER-linked Medicare files to identify 718,907 cancer patients and 1,623,651 control subjects without cancer. The team subtracted the Medicare expenses for matched control subjects from the Medicare expenses for individuals diagnosed with cancer. The balance was the estimated net cost of cancer care per individual.

The mean net 5-year costs of care for elderly individuals varied widely, from less than $20,000 for patients with breast cancer or melanoma to more than $40,000 for patients with lymphoma, brain or other nervous system cancers, or cancers of the esophagus, ovaries, or stomach. Across all cancers, mean net costs were highest in the first 12 months of care and the last 12 months of life, and lowest in the period between the initial phase of care and last year of life.

Yabroff and colleagues note that the study does not evaluate the cost of care in younger cancer patients. As these individuals frequently opt for more aggressive therapies, the cost of services may differ from those reported here. Additionally, as newer, more expensive therapies become routine care, the costs could climb.

Despite these limitations, "these estimates represent a basis for projections of cancer costs that will be particularly important with the growth and aging of the U.S. population," the authors write.

In an accompanying editorial, Joseph Lipscomb, Ph.D., from Emory University in Atlanta carefully analyzes the methods used by Yabroff and colleagues and compares them with other cost-estimate approaches. The high-quality methods lead to solid, if not surprising results. "Few of these individual findings are startling; yet taken together, they provide the scientifically strongest picture yet of the incidence costs of cancer in aggregate and by tumor type for the elderly in the United States," he writes.

Yabroff and colleagues' choice to analyze cost based on the phase of patient care--initial 12 months, continuing care, and last year of life--means that long-term projections are possible. Additionally, "the costing framework…would naturally facilitate the estimation of intervention-specific, patient-specific costs over time--precisely what cost-effectiveness analyses in cancer usually require," Lipscomb writes.


'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Kidney Care Community Applauds National Taxpayers Unions Endorsement of Medicare Reforms to Extend Patient Private Health Insurance Coverage; Calls Proposal Common Sense Coverage Reform
2. Taxpayer Group Offers Blueprint for Beating Medicares Bankruptcy
3. Health Plans Highlight Value of Medicare Advantage Special Needs Plans; Urge Congress to Extend Program
4. Miami Jury Convicts Pharmacy Owner of Medicare Fraud
5. Nations Front Line Caregivers Praise U.S. Representatives Opposition to Medicare-Financed Nursing Home Care Cuts
6. Medicare Prescription Drug Benefit Shows Mixed Results
7. New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits
8. Medicare to consider public opinion about medical maggots
9. Avalere Health Data Finds Four-Tier System Growing Among Medicare Part D Plans
10. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
11. RF Technologies Assists Healthcare Providers in Avoiding Preventable Injury Conditions to be Denied Reimbursement by Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: